Stifel analyst Paul Matteis raised the price target on uniQure BV (NASDAQ: QURE) to $71.00 (from $28.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent'June 17, 2026 1:27 PM Barclays Comments on uniQure BV (QURE) Amid 66% Gain: 'a major positive'June 17, 2026 9:11 AM uniQure (QURE) to resume trading at 7:35 a.m.June 17, 2026 7:22 AM ClearPoint Neuro stock surges on peer's FDA approval planJune 17, 2026 7:21 AM Form 8-K uniQure N.V. For: Jun 17June 17, 2026 7:11 AM uniQure plans BLA submission for Huntington's therapy in Q3 2026June 17, 2026 7:06 AM uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s DiseaseJune 17, 2026 7:05 AM Form 8-K uniQure N.V. For: Jun 10June 15, 2026 4:31 PM Form 144 uniQure N.V. Filed by: Potts JeannetteJune 15, 2026 4:00 PM